400 related articles for article (PubMed ID: 29188322)
1. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
2. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
3. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
4. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, absorption, metabolism, and excretion of [
Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
8. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of [
Mancel V; Mathy FX; Boulanger P; English S; Croft M; Kenney C; Knott T; Stockis A; Bani M
Xenobiotica; 2017 Aug; 47(8):705-718. PubMed ID: 27489076
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
12. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, excretion and pharmacokinetics of [
Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN
Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461
[TBL] [Abstract][Full Text] [Related]
14. Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers.
Zimmermann T; Höchel J; Becka M; Boettger MK; Rohde B; Schug B; Kunert KS; Donath F
Br J Clin Pharmacol; 2018 May; 84(5):865-875. PubMed ID: 29315699
[TBL] [Abstract][Full Text] [Related]
15. Disposition and biotransformation of the antipsychotic agent olanzapine in humans.
Kassahun K; Mattiuz E; Nyhart E; Obermeyer B; Gillespie T; Murphy A; Goodwin RM; Tupper D; Callaghan JT; Lemberger L
Drug Metab Dispos; 1997 Jan; 25(1):81-93. PubMed ID: 9010634
[TBL] [Abstract][Full Text] [Related]
16. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
[TBL] [Abstract][Full Text] [Related]
18. Metabolic profiling of the anti-tumor drug regorafenib in mice.
Wang YK; Xiao XR; Xu KP; Li F
J Pharm Biomed Anal; 2018 Sep; 159():524-535. PubMed ID: 30055476
[TBL] [Abstract][Full Text] [Related]
19. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
Pearson D; Weiss HM; Jin Y; Jaap van Lier J; Erpenbeck VJ; Glaenzel U; End P; Woessner R; Eggimann F; Camenisch G
Drug Metab Dispos; 2017 Jul; 45(7):817-825. PubMed ID: 28442499
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Bathala MS; Masumoto H; Oguma T; He L; Lowrie C; Mendell J
Drug Metab Dispos; 2012 Dec; 40(12):2250-5. PubMed ID: 22936313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
